No connection

Search Results

SNWV

BEARISH
$20.61 Live
SANUWAVE Health, Inc. · NASDAQ
Target $43.5 (+111.1%)
$16.27 52W Range $46.59

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$177.13M
P/E
50.27
ROE
N/A
Profit margin
26.8%
Debt/Equity
14.19
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SNWV exhibits severe fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and an extreme valuation gap. The stock is trading at $20.61, which is astronomically higher than its Graham Number ($1.32) and Intrinsic Value ($2.87). While revenue growth is strong at 26.8%, the company is burdened by a dangerous Debt/Equity ratio of 14.19 and a Price/Book ratio of 109.63. Despite 'strong buy' analyst ratings, the combination of bearish insider selling and a negative forward P/E suggests a high risk of a significant correction.

Key Strengths

Strong gross margins of 77.11%
Consistent revenue growth (26.8% YoY and Q/Q)
Positive current profit margin of 26.82%
Positive Return on Assets (ROA) of 12.07%
Strong analyst target price of $43.50

Key Risks

Extreme overvaluation with a Price/Book ratio of 109.63
Critical leverage levels with a Debt/Equity ratio of 14.19
Weak financial health indicated by a Piotroski F-Score of 3/9
Severe earnings outlook implied by a Forward P/E of -2061.00
Heavy insider liquidation totaling $9.53M in the last 6 months
AI Fair Value Estimate
Based on comprehensive analysis
$3.1
-85.0% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
19
Weak
Value
5
Future
40
Past
35
Health
15
Dividend
0
AI Verdict
High Risk / Speculative Bubble
Key drivers: Extreme P/B ratio, Excessive Debt/Equity, Low Piotroski Score, Insider Selling
Confidence
90%
Value
5/100

Ref P/E 50.27, Graham Number $1.32

Positives
No standout positives identified.
Watchpoints
  • Price is 15x the Graham Number
  • P/B ratio of 109.63 is unsustainable
  • P/E of 50.27 is high given the debt profile
Future
40/100

Ref Growth rates and Forward P/E

Positives
  • Strong YoY revenue growth of 26.8%
Watchpoints
  • Forward P/E of -2061.00 suggests a collapse in expected earnings
Past
35/100

Ref Historical price trends

Positives
  • 5-year growth of 58.2%
Watchpoints
  • 1-year return of -31.2%
  • 6-month return of -39.3%
Health
15/100

Ref Piotroski F-Score and Debt/Equity

Positives
  • Current ratio of 1.38 provides minimal liquidity
Watchpoints
  • Piotroski F-Score 3/9 (Weak)
  • Debt/Equity 14.19 is critically high
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$20.61
Analyst Target
$43.5
Upside/Downside
+111.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SNWV and closest competitors.

Updated 2026-04-17
SNW
SANUWAVE Health, Inc.
Primary
5Y
+58.2%
3Y
+58.2%
1Y
-31.2%
6M
-39.3%
1M
-2.2%
1W
+22.4%
LFC
Lifecore Biomedical, Inc.
Peer
5Y
-52.8%
3Y
+24.4%
1Y
-17.0%
6M
-26.9%
1M
-30.2%
1W
+23.7%
KPT
Karyopharm Therapeutics Inc.
Peer
5Y
-94.7%
3Y
-87.2%
1Y
+100.5%
6M
+45.5%
1M
-8.6%
1W
+35.8%
ING
Inogen, Inc.
Peer
5Y
-88.6%
3Y
-52.4%
1Y
-10.6%
6M
-22.4%
1M
+1.6%
1W
+1.9%
NNO
Nano-X Imaging Ltd.
Peer
5Y
-92.8%
3Y
-63.4%
1Y
-47.9%
6M
-40.0%
1M
-4.6%
1W
+7.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
50.27
Forward P/E
-2061.0
PEG Ratio
N/A
P/B Ratio
109.63
P/S Ratio
4.02
EV/Revenue
4.27
EV/EBITDA
25.13
Market Cap
$177.13M

Profitability

Profit margins and return metrics

Profit Margin 26.82%
Operating Margin 16.66%
Gross Margin 77.11%
ROE N/A
ROA 12.07%

Growth

Revenue and earnings growth rates

Revenue Growth +26.8%
Earnings Growth N/A
Q/Q Revenue Growth +26.81%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
14.19
High debt
Current Ratio
1.38
Good
Quick Ratio
0.97
Poor
Cash/Share
$1.39

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
74.1%
Op. Margin
4.7%
Net Margin
46.7%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
22.07x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
97%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-08
$N/A
2026-03-26
$0.03
-82.3% surprise
2025-11-07
$0.46
+43.8% surprise
2025-08-07
$0.01
+111.1% surprise

Healthcare Sector Comparison

Comparing SNWV against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)
P/E Ratio
50.27
This Stock
vs
85.49
Sector Avg
-41.2% (Discount)
Profit Margin
26.82%
This Stock
vs
-16.16%
Sector Avg
-265.9% (Weaker)
Debt to Equity
14.19
This Stock
vs
3.0
Sector Avg
+373.0% (Higher)
Revenue Growth
26.8%
This Stock
vs
142.9%
Sector Avg
-81.2% (Slower)
Current Ratio
1.38
This Stock
vs
4.65
Sector Avg
-70.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

MANCHESTER MANAGEMENT CO L L C
Divisional Officer
Sell
2025-12-12
20,000 shares · $627,092
MANCHESTER MANAGEMENT CO L L C
Affiliated Person
Sell
2025-12-10
144,810 shares · $4,450,061
MANCHESTER MANAGEMENT COMPANY, LLC
Beneficial Owner of more than 10% of a Class of Security
Sell
2025-12-10
144,810 shares · $4,450,061
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-16
8-K
8-K
2026-03-26
10-K
10-K
2026-03-26

SNWV filed its annual 10-K report on March 26, 2026. While specific financial metrics and risk details were not provided in the excerpts, the filing includes comprehensive disclosures within the Business, Risk Factors, and MD&A sections.

8-K
8-K
2026-03-13

Sunwave (SNWV) filed a current report on March 13, 2026, likely announcing its annual financial results or a material corporate development.

8-K/A
8-K/A
2026-01-15

SNWV filed an amendment to a previously submitted current report.

8-K
8-K
2025-11-07

Sunwave (SNWV) filed an 8-K on November 7, 2025, likely to announce its third-quarter financial results.

10-Q
10-Q
2025-11-06

SNWV filed its 10-Q quarterly report on November 6, 2025. While the filing includes a section for Risk Factors under Item 1A, no specific financial highlights or detailed risk disclosures were provided in the available excerpt.

8-K
8-K
2025-10-30

SNWV filed an 8-K on October 30, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-10-01
8-K
8-K
2025-09-26
8-K
8-K
2025-08-21
8-K
8-K
2025-08-20
8-K
8-K
2025-08-08
10-Q
10-Q
2025-08-07
8-K
8-K
2025-07-31
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
2 analysts
Roth Capital
2026-03-30
reit
Buy Buy

Past News Coverage

Recent headlines mentioning SNWV from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile